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A B S T R A C T
Purpose: To delineate chronological changes of cortical hyperexcitability by long-term follow-up of the
amplitudes of somatosensory evoked potentials (SEPs) in patients with Japanese Unverricht–Lundborg
disease (ULD).
Method: SEPs to median nerve stimulation were repeatedly examined in 7 genetically diagnosed ULD
patients with the mean interval of 11.9 years. The degree of temporal changes in the amplitude of 3 early
cortical components, N20, P25 and N35, to the age was analyzed and compared with that of healthy
subjects.
Results: Their clinical course was almost stable during the follow-up period, namely cessation of
generalized tonic-clonic seizures and little or no progression of myoclonus. SEP amplitudes of P25 and
N35 were enlarged in all patients and were gradually decreased with aging in ULD on average. The degree
of temporal changes of P25 and N35 in ULD was similar or even lower than that of healthy subjects.
Conclusion: Enlarged but relatively stable SEP amplitudes had a consistency with so-called self-limited
clinical course in Japanese ULD. SEP amplitude could be one of the surrogate markers of the degree of
cortical hyperexcitability in ULD during the long-term follow-up period.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Unverricht–Lundborg disease (ULD) is one of the progressive
myoclonus epilepsies that is characterized by myoclonus, epileptic
seizures and cerebellar ataxia, and nowadays is called progressive
myoclonus epilepsy type 1 (EPM1).1 In ULD patients, theAbbreviations: ULD, Unverricht–Lundborg disease; EPM1, progressive myoclonus
epilepsy type 1; SEP, somatosensory evoked potential; GTCS, generalized tonic
clonic seizure.
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights resomatosensory evoked potentials (SEPs) usually show enhanced
cortical components after N20 (i.e., giants SEPs) as a marker of
cortical hyperexcitability to the external stimuli.2,3 Although
the term ‘‘progressive’’ was assigned, it was reported that the
European ULD patients showed self-limited progression in the later
life.4 By investigating neurophysiological correlates of this clinical
course, we just recently reported 2 Japanese ULD patients who
showed clinically no or little progressive course. Their bimodal
waveforms of N35 in the previous SEPs became unimodal over the
course of 16 years, and it suggests decreased cortico-cortical
connectivity and/or cortical excitability.5 We also reported the
amplitudes of the early SEP components (N20, P25 and N35) were
almost stable, although these components were already enlarged in
the previous SEP. However, it is not certain whether waveform
change of N35 is common or not because we studied only 2 patients.
We could not evaluate the chronological changes in amplitudes of
each cortical SEP component, either. Herewith we extensively
evaluated 5 more genetically proven ULD patients.served.
K. Kobayashi et al. / Seizure 23 (2014) 746–750 747In this report, we further described the temporal changes in SEP
amplitudes of a total of 7 Japanese ULD patients to delineate the
chronological changes of responsive, cortical hyperexcitability.
Only abstract is available for this study.6
2. Patients and methods
We recruited 7 Japanese patients with genetically diagnosed
ULD (4 men and 3 women; mean age at the ﬁrst SEP examination
of 27.6 years, ranged from 17 to 42 years). During the follow-up
period, we collected the changes in the frequency of generalized
tonic clonic seizures (GTCSs), and the degree of myoclonus for
each patient by using the simpliﬁed myoclonus rating scale as
follows,4 0 = no myoclonus; 1 = minor myoclonus, no interference
with daily living; 2 = mild myoclonus, interference with
ﬁne movements and/or speech, no interference with walking;
3 = moderate myoclonus, patient still able to walk without
support; 4 = moderate to severe myoclonus, patient able to stand,
unable to walk without support; 5 = severe myoclonus, patient
wheelchair-bound or bedridden.
The SEPs were not recorded with completely the same
equipment and condition, since the patients belonged to several
institutes and the repeated examination were done with the mean
interval of 11.9 years (ranged from 4 to 16 years). Recording
conditions were quite consistent at least within each patient.
Furthermore, as compared with previous study,5 the overall
recording condition was essentially consistent except for stimulus
frequency in several patients as follows. The median nerve was
stimulated at the wrist at a ﬁxed rate of 1.1–3.0 Hz (1.1 Hz in 3
patients and 2.0 Hz in 4 for the previous recording; 1.1 Hz in 5 and
3.0 in 2 for the present recording) and the stimulus intensity was
adjusted to produce a clear twitch of the thenar muscle. Short
latency SEPs were recorded from C3/C4 according to the
International 10–20 System or CP3/CP4 by 10-10 System of
the American EEG Society. The electrode impedance was kept
below 5 kV. The ipsilateral earlobe to the stimulated hand (A1 or
A2) or the linked earlobes (A1 + A2) were used as the reference. The
bandpass ﬁlter was within the range of 0.5–3000 Hz. At least 200
responses were averaged.Table 1
Medications at the previous and present SEP recording in 7 patients (mg/day).
Previous 
Age at SEP 
Patient 1 42 VPA 1,400, CZP 4.5, PB 120, Piracetam 15,000 
Patient 2 32 VPA 3,600, CZP 12, PHT 300, CBZ 400 
Patient 3 24 VPA 1,100, CZP 6, ZNS 200 
Patient 4 31 VPA 1,200, PB 90, ZNS 200 
Patient 5 17 VPA 1,200, CZP 1.3, PB 40, PRM 400 
Patient 6 24 VPA 800, CBZ 200 
Patient 7 23 VPA 800, CZP 2, Piracetam 12,000 
VPA: valproic acid, CZP: clonazepam, PB: phenobarbital, PHT: phenytoin, CBZ: carbam
Table 2
Latency and amplitude of cortical components of SEPs in 7 patients, latency (ms)/amp
Previous 
Age at SEP N20 P25 N35 
Patient 1 42 20.6/1.3 26.6/6.6* 30.9/10.3*
Patient 2 32 19.2/0.2 24.8/5.5 31.5/11.8*
Patient 3 24 23.7/0.0 29.1/5.2 37.9/8.3 
Patient 4 31 23.8/0.4 32.0/17.4* 38.7/19.7*
Patient 5 17 20.0/0.2 26.0/21.0* 32.6/24.8*
Patient 6 24 20.4/2.3 26.6/5.8 34.9/4.7 
Patient 7 23 14.2/1.8 20.2/11.9* 31.8/10.4*
Average  S.D. 27.6 20.3  3.2/0.9  0.9 26.5  3.6/10.5  6.4 34.0  3.2/12.9
* Giant SEP: P25 > 6.3 or N35 > 9.8 mV 7We adopted 3 components of N20, P25 and N35. Amplitudes of
P25 and N35 were measured from the preceding opposite peak and
those of N20 were measured from the baseline. An SEP was judged
as ‘‘giant’’ when P25 was more than 6.3 mV or N35 was more than
9.8 mV.7 We also compared the amplitudes of the 3 components of
ULD patients in the previous and present states with those of
healthy subjects (N = 19; 11 men and 8 women; mean age at the
SEP examination of 49 years, ranged from 22 to 74 years) by Mann–
Whitney U test. A tangential component of N30–P30 was not
adopted in this study, since we could not detect the reliable N30–
P30 from shortage of the number of the recorded electrodes.
In order to evaluate the chronological changes in SEP amplitude
in ULD, we compared the early cortical components of SEPs
between previous and present states by Wilcoxon signed-rank test.
In addition, we analyzed the relationship between the age at SEP
recording and its amplitudes. Namely we calculated the averaged
value of the ages and amplitudes of 7 patients both at previous and
present SEP recording, and then extrapolated the chronological
changes. Since SEP amplitude increased with aging even in healthy
subjects,8,9 we compared the gradient of ULD patients with those
of 19 healthy subjects as reported previously.9
3. Results
As for the clinical symptoms, all the patients showed a cessation
of GTCSs and a stable or little worsened myoclonus. The
medications at the previous and present SEP recording are shown
in Table 1. During the follow-up period, the dosage of the
medications did not show clear tendency. Namely, medication was
increased in 4 patients (Patient 3, 4, 5, and 6) whereas it was
decreased in 3 patients (Patient 1, 2, and 7). The averaged
simpliﬁed myoclonus rating scale of 7 patients indicated almost
stable but moderately severe, 3.4 and 3.9 at the previous and
present recording, respectively.
In the previous recording, N20, P25 and N35 amplitudes
(mean  S.D.) in 7 ULD patients were 0.9  0.9 mV, 10.5  6.4 mV and
12.9  7.0 mV, and those in the present evaluation were 2.3  1.6 mV,
9.9  6.1 mV and 10.8  4.0 mV, respectively (Table 2). Both in the
previous and present recording, the amplitudes of N20 in ULD werePresent
Age at SEP
58 VPA 700, CZP 6, PB 60, Piracetam 6,000
48 VPA 2,000, CZP 8, ZNS 300, DZP 5
34 VPA 1,800, CZP 6, ZNS 200, Piracetam 33,000
42 VPA 1,200, CZP 6, PB 60, ZNS 200, Piracetam 27,000
34 VPA 1,800, CZP 4, ZNS 600, PRM 300, AZM 250
33 VPA 1,400, PB 50, ZNS 200
27 VPA 600, CZP 2, Piracetam 12,000
azepine, ZNS: zonisamide, DZP: diazepam, PRM: primidone, AZM: acetazolamide.
litude (mV).
Present
Age at SEP N20 P25 N35
58 20.1/2.5 25.4/9.5* 30.8/10.9*
48 20.7/0.8 24.9/4.7 32.3/13.0*
34 20.6/2.0 25.3/6.0 31.4/10.0*
42 20.9/5.1 26.6/22.4* 33.1/18.2*
34 20.3/1.1 25.8/6.6* 31.0/5.6
33 20.5/1.3 27.4/7.8* 35.3/7.6
27 18.5/3.6 24.0/12.3* 32.7/10.3*
  7.0 39.4 20.2  0.8/2.3  1.6 25.6  1.1/9.9  6.1 32.4  1.5/10.8  4.0
Fig. 1. Correlation between the age at SEP recording and its amplitudes in 7 ULD patients. Values of N20 (A), P25 (B) and N35 (C) (different colored lines) and the gradients of
their temporal changes drawn by calculating the averaged value of the ages and amplitudes between previous and present SEP recordings (black lines) in 7 patients are
compared with linear regression curves of 19 healthy subjects (gray lines). N20 amplitudes were much smaller and P25 and N35 amplitudes larger in ULD patients. As for the
components associated with giant SEP (i.e., P25 and N35), 7 ULD patients showed a tendency of slight decrease in amplitude during the follow-up period, and the degree of its
tendency was even lower than that of healthy subjects. (For interpretation of reference to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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the amplitudes of P25 and N35 in ULD were higher than those of
healthy subjects and only N35 amplitudes reached statistical
signiﬁcance (p < 0.05). All 7 patients fulﬁlled the criteria of the giant
SEPs at least once during their clinical course.
The amplitudes of P25 and N35 in some of the ULD patients
tended to increase during the follow-up period, but no signiﬁcant
difference in amplitude was found between previous and
present data by Wilcoxon signed-rank test. Whereas, only 1 patient
(Patient 5) showed relatively drastic decrease in SEP amplitude for
P25 and N35 (Fig. 1(b) and (c)). In total, the gradients of temporal
changes of N20, P25 and N35 amplitudes for age in the 7 ULD
patients were 0.119, 0.051, and 0.178, respectively. As
compared with healthy subjects (N20: 0.048, P25: 0.139, N35:
0.089), that of P25 and N35, were even lower than those of healthy
subjects (Fig. 1). Namely, enhanced amplitude of P25 and N35
reﬂects the responsive, cortical hyperexcitability across all the
7 patients, but the degree of its gradient in temporal change for
aging is not increased at all. When 1 patient (Patient 5) was
excluded because she showed dramatically decrease in ampli-
tudes, the gradients of temporal changes of N20, P25 and N35
amplitudes for age in the 6 ULD patients were quite similar to those
of aging in healthy subjects, i.e., 0.141, 0.156, and 0.073,
respectively (not shown in the ﬁgure).
The waveform change of N35 from bimodal to unimodal over
the course was observed only in 2 out of 7 patients, both of whom
we reported in the previous report.5
4. Discussion
We demonstrated that SEP amplitudes were enlarged or giant
in genetically diagnosed ULD patients throughout the follow-up
period, that was quite consistent with previous reports.
We also showed that once enlarged SEP amplitude of P25 and
N35 gradually decreased on average with aging in ULD. Indeed, 5
patients for P25 and 4 patients for N35 demonstrated that enlarged
SEP amplitude gradually increased with aging, but the degree of
increment was quite comparable to that of aging in healthy
subjects (Fig. 1). Namely, most likely we were able to demonstrate
that responsive cortical hyperexcitability was not progressive for
aging but relatively stable in the primary sensori-motor cortices in
Japanese ULD. These electrophysiological ﬁndings in quite parallel
with clinical course in our patients were quite consistent with self-
limited clinical course as reported previously.4 Therefore, SEP
amplitude could be one of the surrogate markers of the degree of
cortical excitability and at least a part of pathophysiology in
ULD during the long-term follow-up period. However, it is unclear
that self-limited progression was observed in all Japanese ULD
patients, since one of the patients (Patient 5), who showed a little
worsened myoclonus, showed relatively drastic decrease in SEP
amplitude. It might be explained by the paradoxical association
between giant SEP and the degree of myoclonus, which was clearly
reported in patients with cortical myoclonus previously.10
In addition, some ULD patients in other reports with
genetically diagnosed show continuous progression in terms of
clinical symptoms as well as electrophysiological results.11 In our
previous report we mentioned the waveform change of N35 from
bimodal to unimodal could reﬂect a lesser degree of cortico-
cortical connectivity and/or decreased cortical hyperexcitability
in ULD patients. The additionally recruited 5 patients did
not show similar waveform change of N35 component,
which suggests not only this waveform change but also
chronological changes in SEP amplitudes contribute to self-
limited progression.
Further case accumulation showing variable clinical course is
indispensable to further clarify the clinico-electorophysiologicalcorrelates and to solve these clinical questions in patients with
ULD. The current long-term observation in this study started
mostly after age 20 years in 6 out of 7 patients, but it was done until
before 50 years in 6 out of 7 patients. Therefore, it may not be
completely excluded that ULD patients in much older age more
than 50 years are actually so stable. Thus, it is important to
continue the evaluation of our patients to see if changes in SEP can
manifest in older patients.
There are several limitations in this study. Firstly, the change of
SEP amplitude over a decade might be due to chronic exposure to
antiepileptic or antimyoclonic drugs. In general, most antiepilep-
tic drugs seem to decrease the SEP amplitude.12 The dosages of
these drugs were not completely the same during the follow-up
period as well. Secondly, as mentioned in Section 2, the recording
conditions were not completely the same among studied patients
and within each patient. However, except stimulus rate, we
consider that the inﬂuence of the different recording conditions
on the SEP amplitude was quite small. With regard to the stimulus
rate, in the previous reports, the amplitude of P25 decreased and
N35 was not signiﬁcantly altered once the stimulus rate gradually
increased from 1.0 to 5.0 Hz.13,14 In our study, the stimulus rate
increased from 2.0 Hz to 3.0 Hz in 2 patients (Patients 5 and 6), and
that decreased from 2.0 Hz to 1.1 Hz in the other 2 patients
(Patient 3 and 4) between previous and present recordings. The
change of amplitude, such as decreased amplitude of P25 only in
Patient 5, might be partly inﬂuenced by the change of stimulus
rate. Despite these limitations, our study has some value in
evaluating long-term clinico-electorophysiological changes in
Japanese ULD.
5. Conclusions
We demonstrated that SEP amplitudes were enlarged or giant
in genetically diagnosed ULD patients throughout the follow-up
period. We also showed that once enlarged SEP amplitude of P25
and N35 gradually decreased with aging in ULD. Enlarged but
relatively stable or gradually decreased SEP amplitudes had a
consistency with so-called self-limited clinical course in ULD. SEP
amplitude could be one of the surrogate markers of the degree of
cortical hyperexcitability in ULD during long-term follow-up
period.
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